Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with type 1 diabetes and recurrent severe ...

The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Diabetes is a metabolic disorder caused by dysfunction in the pancreas, the organ responsible for regulating blood sugar levels. Within the pancreas, islet cells secrete insulin to lower blood sugar.

A recent study released by researchers from Pohang University of Science and Technology (POSTECH) opens the door for more ...

PDX-1 is a critically important transcription factor for the insulin promoter, is absent in glucotoxic islets, and, when transfected into glucotoxic ß-cells, improves insulin promoter activity.

DSMB supports advancement for Sernova’s clinical trialStudy is on track to meet key clinical trial endpointsLONDON, Ontario and BOSTON, April ...

Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...